Construction and Validation of a Novel Immunosignature for Overall Survival in Uveal Melanoma.
immune microenvironment
immunological marker
overall survival
prognostic signatures
uveal melanoma
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
05
2021
accepted:
18
08
2021
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and immune infiltration plays a crucial role in the prognosis of UM. This study aimed to generate an immunological marker-based predictive signature for the overall survival (OS) of UM patients. Single-sample gene-set enrichment analysis (ssGSEA) was used to profile immune cell infiltration in 79 patients with UM from The Cancer Genome Atlas (TCGA) database. Univariate and multivariate least absolute shrinkage and selection operator (LASSO) Cox regressions were used to determine the prognostic factors for UM and construct the predictive immunosignature. Receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration curves were performed to evaluate the clinical ability and accuracy of the model. In addition, the predictive accuracy was compared between the immunosignature and the Tumor, Node, Metastasis (TNM) staging system of American Joint Committee on Cancer (AJCC). We further analyzed the differences in clinical characteristics, immune infiltrates, immune checkpoints, and therapy sensitivity between high- and low-risk groups characterized by the prognostic model. Higher levels of immune cell infiltration in UM were related to a lower survival rate. Matrix metallopeptidase 12 (MMP12), TCDD inducible poly (ADP-ribose) polymerase (TIPARP), and leucine rich repeat neuronal 3 (LRRN3) were identified as prognostic signatures, and an immunological marker-based prognostic signature was constructed with good clinical ability and accuracy. The immunosignature was developed with a concordance index (C-index) of 0.881, which is significantly better than that of the TNM staging system ( We developed a novel immunosignature constructed by MMP12, TIPARP, and LRRN3 that could effectively predict the OS of UM.
Identifiants
pubmed: 34552928
doi: 10.3389/fcell.2021.710558
pmc: PMC8450517
doi:
Types de publication
Journal Article
Langues
eng
Pagination
710558Informations de copyright
Copyright © 2021 Gu, Gu, Wang, Yao and Zhou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2888-95
pubmed: 19234348
Front Genet. 2020 Sep 02;11:990
pubmed: 32983229
PLoS One. 2013 May 22;8(5):e64702
pubmed: 23717651
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Med Chem. 2020 Nov 12;63(21):12911-12920
pubmed: 33107733
Invest Ophthalmol Vis Sci. 2011 Feb 03;52(2):643-50
pubmed: 20811059
Cancer Manag Res. 2019 Oct 18;11:8991-9004
pubmed: 31695491
J Immunol. 1998 Jun 15;160(12):5693-6
pubmed: 9637476
Mol Neurobiol. 2018 Feb;55(2):1405-1409
pubmed: 28155200
Eur J Immunol. 1992 Jan;22(1):165-73
pubmed: 1530916
Mol Ther Nucleic Acids. 2020 Aug 29;22:298-309
pubmed: 33230435
PLoS One. 2016 Oct 20;11(10):e0164292
pubmed: 27764126
Nat Commun. 2021 Jan 20;12(1):481
pubmed: 33473108
Cancer Biother Radiopharm. 2019 Dec;34(10):626-633
pubmed: 31621397
Front Oncol. 2019 May 01;9:325
pubmed: 31119098
Eur J Cancer. 2017 Sep;82:56-65
pubmed: 28648699
Cancer Immunol Immunother. 2017 Jul;66(7):903-912
pubmed: 28391358
J Crohns Colitis. 2021 Apr 09;:
pubmed: 33836047
Immunology. 2009 Jul;127(3):299-311
pubmed: 19538249
J AAPOS. 2012 Feb;16(1):10-6
pubmed: 22370659
Med Oncol. 2013 Dec;30(4):688
pubmed: 23959449
Br J Ophthalmol. 2006 Feb;90(2):213-7
pubmed: 16424536
Semin Diagn Pathol. 2016 May;33(3):141-7
pubmed: 26972224
Front Immunol. 2012 Nov 27;3:338
pubmed: 23230433
Br J Cancer. 2017 Sep 5;117(6):884-887
pubmed: 28809862
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
J Cancer. 2020 Mar 4;11(11):3172-3179
pubmed: 32231721
Cancers (Basel). 2019 Oct 30;11(11):
pubmed: 31671564
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2572-80
pubmed: 19151381
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Ther Adv Med Oncol. 2020 Oct 22;12:1758835920965852
pubmed: 33149769
Invest Ophthalmol Vis Sci. 2001 Feb;42(2):313-7
pubmed: 11157859
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Nucleic Acids Res. 2013 Feb 1;41(3):1604-21
pubmed: 23275542
PLoS One. 2012;7(7):e41355
pubmed: 22844464
Clin Cancer Res. 2011 Nov 1;17(21):6681-92
pubmed: 21908575
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Cell Death Dis. 2013 Oct 10;4:e846
pubmed: 24113180
Adv Cancer Res. 2001;83:117-58
pubmed: 11665717
Immunity. 2009 Nov 20;31(5):787-98
pubmed: 19879162
Br J Cancer. 2014 Sep 23;111(7):1373-80
pubmed: 25058347
Invest Ophthalmol Vis Sci. 1993 Jul;34(8):2603-6
pubmed: 8325762
Ophthalmology. 2016 May;123(5):1118-28
pubmed: 26923342
Genome Biol. 2014 Mar 03;15(3):R47
pubmed: 24580837
Clin Cancer Res. 2010 Dec 15;16(24):6083-92
pubmed: 20975103
Invest Ophthalmol Vis Sci. 2012 Aug 09;53(9):5370-8
pubmed: 22743317